Sign in

CIK 0001821586 · Large accelerated filer

MoonLake Immunotherapeutics

Sign in to watch
Ticker
MLTX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
Cayman Islands
Entity type
operating
Phone
41 41 510 8022
Business address
DORFSTRASSE 29, ZUG, Switzerland, 6300
Former names
Helix Acquisition Corp
  1. 4 Conversion Chief Scientific Officer acquired 111,949 shares (conversion)
  2. 4 Open-market sale Director sold 2,000,000 shares at $50.00 ($100,003,200)
  3. 4 Open-market sale Director sold 171,000 shares at $53.72 ($9,186,120)
  4. 4 Derivatives Options or other derivatives
  5. 4 Derivatives Options or other derivatives
  6. 4 Derivatives Options or other derivatives
  7. 4 Derivatives Options or other derivatives
  8. 4 Derivatives Options or other derivatives
  9. 4 Derivatives Options or other derivatives
  10. 4 Planned sale Chief Executive Officer sold 123,615 shares at an average $55.03 ($6,803,044)
  11. 4 Planned sale Chief Scientific Officer sold 118,922 shares at $55.00 ($6,540,710)
  12. 4 Planned sale Chief Executive Officer sold 1,125 shares at $55.27 ($62,179)
  13. 4 Planned sale Chief Scientific Officer sold 21,078 shares at an average $57.33 ($1,208,418)
  14. 4 Planned sale Chief Executive Officer sold 60,000 shares at an average $59.26 ($3,555,400)
  15. 4 Planned sale Chief Scientific Officer sold 60,000 shares at an average $60.91 ($3,654,800)
  16. 4 Planned sale Chief Financial Officer sold 100,000 shares at an average $59.17 ($5,917,368)
  17. 4 Open-market buy 10% owner bought 58,839 shares at $59.90 ($3,524,297)
  18. 4 Open-market buy 10% owner bought 293,212 shares at an average $57.30 ($16,800,343)
  19. 4 Conversion Director acquired 342,980 shares (conversion)
  20. 4 Conversion Chief Financial Officer acquired 62,972 shares (conversion)

Page 3 of 5 · 97 filings